Built from Galmed Pharmaceuticals Ltd.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$2.35-5.6%Nov 13 close
Next earnings: November 25, 2026
Figures through June 30, 2026, from the 6-K filed September 2, 2026
Not rated
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 12 quarters of Galmed Pharmaceuticals Ltd.’s grade history. The other 10 go back to March 2017.